Literature DB >> 30155802

Risks of Opioids in ST-Elevation Myocardial Infarction: A Review.

Anne Henrieke Tavenier1, Renicus Suffridus Hermanides2, Jan Paul Ottervanger2, Peter Gerrit Johannes Ter Horst3, Elvin Kedhi2, Adriaan W J van 't Hof4,5.   

Abstract

Although opioids are recommended and frequently used in the acute phase of ST-elevation myocardial infarction (STEMI), their use is accompanied by serious side effects. In particular, gastrointestinal adverse effects may disturb absorption of essential oral medication like platelet inhibitors. This may cause suboptimal platelet inhibition and increased risk of acute stent thrombosis. Some clinical studies have already demonstrated these negative results. Alternative strategies to optimize platelet inhibition and pain relief in STEMI are being investigated. Clinicians should become more aware of the potential side effects of opioids in STEMI.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30155802     DOI： 10.1007/s40264-018-0710-y

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


  44 in total

Review 1.  Stent thrombosis: a clinical perspective.

Authors:  Bimmer E Claessen; José P S Henriques; Farouc A Jaffer; Roxana Mehran; Jan J Piek; George D Dangas
Journal:  JACC Cardiovasc Interv       Date:  2014-10       Impact factor: 11.195

2.  Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial.

Authors:  Dimitrios Venetsanos; Sofia Sederholm Lawesson; Eva Swahn; Joakim Alfredsson
Journal:  Thromb Res       Date:  2016-10-15       Impact factor: 3.944

3.  Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Authors:  Deepak L Bhatt; Gregg W Stone; Kenneth W Mahaffey; C Michael Gibson; P Gabriel Steg; Christian W Hamm; Matthew J Price; Sergio Leonardi; Dianne Gallup; Ezio Bramucci; Peter W Radke; Petr Widimský; Frantisek Tousek; Jeffrey Tauth; Douglas Spriggs; Brent T McLaurin; Dominick J Angiolillo; Philippe Généreux; Tiepu Liu; Jayne Prats; Meredith Todd; Simona Skerjanec; Harvey D White; Robert A Harrington
Journal:  N Engl J Med       Date:  2013-03-10       Impact factor: 91.245

4.  Acetaminophen-Induced Changes in Systemic Blood Pressure in Critically Ill Patients: Results of a Multicenter Cohort Study.

Authors:  Aymeric Cantais; David Schnell; François Vincent; Zeineb Hammouda; Sophie Perinel; Sarah Balichard; Fekri Abroug; Fabrice Zeni; Ferhat Meziani; Caroline Bornstain; Michael Darmon
Journal:  Crit Care Med       Date:  2016-12       Impact factor: 7.598

Review 5.  The on- and off-target effects of morphine in acute coronary syndrome: A narrative review.

Authors:  Cian P McCarthy; Kieran V Mullins; Sunjeet S Sidhu; Steven P Schulman; John W McEvoy
Journal:  Am Heart J       Date:  2016-04-16       Impact factor: 4.749

6.  Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl).

Authors:  John W McEvoy; Khalil Ibrahim; Thomas S Kickler; William A Clarke; Rani K Hasan; Matthew J Czarny; Ali R Keramati; Rakesh R Goli; Travis P Gratton; Jeffrey A Brinker; Matthews Chacko; Chao-Wei Hwang; Peter V Johnston; Julie M Miller; Jeffrey C Trost; William R Herzog; Roger S Blumenthal; David R Thiemann; Jon R Resar; Steven P Schulman
Journal:  Circulation       Date:  2017-10-18       Impact factor: 29.690

Review 7.  Opioids and cardioprotection.

Authors:  J E Schultz; G J Gross
Journal:  Pharmacol Ther       Date:  2001-02       Impact factor: 12.310

8.  The presence of mu-, delta-, and kappa-opioid receptors in human heart tissue.

Authors:  Piotr Sobanski; Malgorzata Krajnik; Mohammed Shaqura; Elzbieta Bloch-Boguslawska; Michael Schäfer; Shaaban A Mousa
Journal:  Heart Vessels       Date:  2014-01-05       Impact factor: 2.037

9.  Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: enhancement by opioid action.

Authors:  Ilias Rentoukas; Georgios Giannopoulos; Andreas Kaoukis; Charalampos Kossyvakis; Konstantinos Raisakis; Metaxia Driva; Vasiliki Panagopoulou; Konstantinos Tsarouchas; Sofia Vavetsi; Vlasios Pyrgakis; Spyridon Deftereos
Journal:  JACC Cardiovasc Interv       Date:  2010-01       Impact factor: 11.195

10.  Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.

Authors:  Jacek Kubica; Piotr Adamski; Małgorzata Ostrowska; Joanna Sikora; Julia Maria Kubica; Wiktor Dariusz Sroka; Katarzyna Stankowska; Katarzyna Buszko; Eliano Pio Navarese; Bernd Jilma; Jolanta Maria Siller-Matula; Michał Piotr Marszałł; Danuta Rość; Marek Koziński
Journal:  Eur Heart J       Date:  2015-10-21       Impact factor: 29.983
View more
  2 in total

1.  Integrated Multichip Analysis and WGCNA Identify Potential Diagnostic Markers in the Pathogenesis of ST-Elevation Myocardial Infarction.

Authors:  Yingliang Liang; Wandang Wang; Qiufang Huang; Hui Chen
Journal:  Contrast Media Mol Imaging       Date:  2022-04-07       Impact factor: 3.009

Review 2.  Mitochondria as a therapeutic target for cardiac ischemia‑reperfusion injury (Review).

Authors:  Wenwen Marin; Dennis Marin; Xiang Ao; Ying Liu
Journal:  Int J Mol Med       Date:  2020-12-16       Impact factor: 4.101
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.